GHK-Cu Real-World Evidence: Registries, Case Series, and Observational Data

Is there a registry, cohort or case series?

We found no GHK-Cu patient registry, claims-database analysis, electronic-health-record cohort or case series with standardized outcomes. FDA defines real-world data as information on patient health status or the delivery of care routinely collected from electronic health records, claims, registries and similar sources, and real-world evidence as the clinical evidence about a medical product derived from analysing that data; the agency says it has long used such data mainly to monitor postmarket safety of approved drugs, with support for effectiveness on a more limited basis [10].

What human randomized trials have been published?

Three, and they tested three different formulations.

A prospective randomized evaluator-blinded trial enrolled 86 evaluable patients with venous stasis ulcers. A 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo on ulcer size, while silver sulfadiazine 1% in a cream reduced ulcer size compared with both [2].

A multicenter randomized evaluator-blinded placebo-controlled trial in diabetic neuropathic ulcers reported benefit; the abstract does not give the number of patients. Every patient received sharp debridement at entry, standardized pressure-relieving footwear and education. In plantar ulcers, GHK-Cu gel produced a median 98.5% area closure versus 60.8% with vehicle (p<0.05), and the rate of closure was three times faster than with standard care and vehicle. Among plantar ulcers treated immediately after debridement, infections occurred in 7% with GHK-Cu gel versus 34% with vehicle (p<0.05). In ulcers larger than 100 mm² at study entry the gap was wider, a median 89.2% closure versus -10.3% with vehicle (p<0.01). The authors note that treatment had to begin immediately after the initial debridement [3].

Thirteen patients completed the randomized trial of post-treatment skin care with or without GHK-Cu after circumoral skin was resurfaced with a CO2 laser. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved, and all patients improved in wrinkles and overall skin quality with no difference between groups. A validated patient questionnaire did show a significant difference in overall skin quality favouring GHK-Cu (P=.04) [1].

What does the 2026 systematic review cover?

The review mapped GHK-Cu literature published between 2005 and 2026. Searches across PubMed, ScienceDirect and the Cochrane CENTRAL registry returned 1,247 records, and 64 were retained for qualitative synthesis. Its authors note that microneedle delivery of GHK-Cu, which in vitro and porcine ex vivo work shows greatly increases skin uptake, has not yet been evaluated in a registered, adequately powered human randomized controlled trial [4].

What do the laboratory studies show?

The mechanism story comes from laboratory and animal work, largely from the researchers who proposed it. Their review reports that GHK stimulates both the synthesis and breakdown of collagen and glycosaminoglycans, modulates metalloproteinases and their inhibitors, stimulates decorin, attracts immune and endothelial cells to an injury, and accelerates wound healing in dogs, rats, mice and pigs, and that it can up- and downregulate at least 4,000 human genes [11]. These are proposed and preclinical actions, not demonstrated clinical outcomes.

The individual studies behind that summary are small and laboratory-based. GHK-Cu stimulated collagen synthesis in fibroblast cultures, with the effect starting between 10⁻¹² and 10⁻¹¹ M and peaking at 10⁻⁹ M, independent of any change in cell number [12]. In rats with implanted wound chambers, injected GHK-Cu produced concentration-dependent increases in dry weight, DNA, total protein, collagen and glycosaminoglycan content, with collagen stimulation twice that of noncollagen proteins and increased type I and type III collagen mRNAs but not TGF-beta mRNA [13]. In skin-equivalent models, copper-GHK increased keratinocyte proliferation and p63 positivity [14].

What is known about safety

No adverse-event rates were found in the abstracts of the three trials [1][2][3]. For the injectable route, FDA states that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [8].

What is the current regulatory status?

Non-injectable GHK-Cu sits in category 1 of FDA's interim policy for nominated bulk drug substances — the group still under evaluation, for which FDA says it generally does not intend to act against compounders when the conditions in its guidance are met [9][5]. Injectable GHK-Cu appears separately in FDA's table of substances whose nominations were withdrawn, alongside the immunogenicity concern [8]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027, and no vote has happened yet [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [15].

A topical copper peptide product stays a cosmetic unless it claims to treat disease or to change the structure or function of the body, which would make it a drug [7].